Schering AG and AstraZeneca to develop anti-inflammatory agents
Schering AG possesses an advanced collection of identified SEGRAs, which could be used to treat a number of diseases. Schering and AstraZeneca will undertake a joint R&D program
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.